It has also cancelled a sub-Saharan Africa collaboration agreement with the UK group GlaxoSmithKline.
The deal, first announced on September 12, appears to be an exchange valued at £45m.
This was the option amount agreed to include China when Aspen acquired the rights to Fraxiparine and Arixtr in most countries in 2014.
GlaxoSmithKline, in turn, has paid Aspen £45m to cancel its sub-Saharan Africa collaboration agreement with subsidiary, Pharmacare.
Aspen said on Tuesday it "is pleased to announce that these transactions completed on December 31".
In the September statement, Aspen said the sub-Saharan Africa collaboration generated about R2,1bn in revenue during its 2015 financial year.
Ending the collaboration "would enable GlaxoSmithKline to focus on its recently communicated strategic initiatives in Africa".
"Aspen is retaining its existing African operations in Kenya, Tanzania, Nigeria, Ghana and Uganda, and will also continue its exports into approximately 15 other African countries. In addition, Aspen will continue to seek other opportunities in the region should they fit with its strategic goals," it said in September.
For more than two decades, I-Net Bridge has been one of South Africa’s preferred electronic providers of innovative solutions, data of the highest calibre, reliable platforms and excellent supporting systems. Our products include workstations, web applications and data feeds packaged with in-depth news and powerful analytical tools empowering clients to make meaningful decisions.
We pride ourselves on our wide variety of in-house skills, encompassing multiple platforms and applications. These skills enable us to not only function as a first class facility, but also design, implement and support all our client needs at a level that confirms I-Net Bridge a leader in its field.
Go to: http://www.inet.co.za
